Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Kerstin N. Vokinger Clear advanced filters

  • Less than 2% of artificial intelligence devices authorized by the US Food and Drug Agency are prognostic, with prediction horizons ranging from minutes to several years. As the number of prognostic AI devices could increase, it is important to address the accompanying regulatory and ethical challenges.

    • Urs J. Muehlematter
    • Kerstin Noelle Vokinger
    Comments & Opinion
    Nature Machine Intelligence
    Volume: 8, P: 138-143

  • Publicly funded research leads to the development of many new drugs, but the profits are largely reaped by big pharmaceutical companies through exclusive licensing deals, mergers and acquisitions, which can reduce competition and patients’ access to medicines.

    • Melissa Newham
    • Kerstin N. Vokinger
    Comments & Opinion
    Nature Medicine
    Volume: 28, P: 1342-1344

  • Legislators in the USA have been discussing reforms to reduce the high cost of brand-name drugs, which are much higher in the USA than in other industrialized countries. One solution is to actively negotiate prices based on drugs’ clinical benefits. We discuss two important complexities from such an approach: drugs that have been approved for multiple indications and as part of a combination regimen.

    • Kerstin N. Vokinger
    • Aaron S. Kesselheim
    Comments & Opinion
    Nature Reviews Clinical Oncology
    Volume: 19, P: 1-2

  • The regulatory landscape for artificial intelligence (AI) is shaping up on both sides of the Atlantic, urgently awaited by the scientific and industrial community. Commonalities and differences start to crystallize in the approaches to AI in medicine.

    • Kerstin N. Vokinger
    • Urs Gasser
    Comments & Opinion
    Nature Machine Intelligence
    Volume: 3, P: 738-739

  • Vokinger et al. discuss potential sources of bias in machine learning systems used in medicine. The authors propose solutions to mitigate bias across the different stages of model development, from data collection and preparation to model evaluation and application.

    • Kerstin N. Vokinger
    • Stefan Feuerriegel
    • Aaron S. Kesselheim
    Comments & OpinionOpen Access
    Communications Medicine
    Volume: 1, P: 1-3